Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesTemporary CodesHCPCS hcpcs-q2043-sipuleucel-t-cellular-immunotherapy-infusion
    Ask Trek AI about this page

    HCPCS Level II Q2043: Sipuleucel‑T Autologous Cell Immunotherapy, Per Infusion

    HCPCS Level II code Q2043 describes administration of sipuleucel‑T consisting of a minimum of 50 million autologous CD54+ cells activated with PAP‑GM‑CSF, including leukapheresis and all preparatory procedures, billed per infusion; this represents a cellular immunotherapy service typically delivered in an outpatient infusion center or specialized oncology clinic and involves leukapheresis, cell processing, and subsequent infusion visits.

    For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.

    Customize your policy alerts

    Sign up for hcpcs Q2043 policy alerts

    Get alerted when payer policies referencing Q2043 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 72-year-old man with asymptomatic metastatic castration-resistant prostate cancer (mCRPC) presents to the infusion center for manufacture and infusion of sipuleucel-t. The clinical workflow begins with a referral from the medical oncologist to a leukapheresis-capable infusion center. Baseline evaluation includes review of prior therapies, performance status, and documentation of metastatic disease (often bone-predominant) and castrate-resistant status. The patient undergoes leukapheresis to collect peripheral blood mononuclear cells, which are shipped to the manufacturer for ex vivo activation with PAP-GM-CSF to produce the autologous cellular immunotherapy product. On a scheduled infusion day (typically three infusions at approximately two-week intervals), the patient is pre-assessed by oncology nursing for vital signs and infusion readiness; premedication (acetaminophen and/or antihistamine) is given per protocol. The sipuleucel-t product is thawed and infused intravenously over the recommended time with monitoring for infusion reactions. Documentation includes product lot numbers, cell counts (minimum 50 million CD54+ autologous cells), dates of leukapheresis and infusion, and any acute reactions. Billing uses HCPCS Level II code Q2043 for each infusion and may include appropriate modifiers for place of service, provider attribution, or unusual circumstances. Typical site of service is an outpatient hospital infusion center or freestanding oncology infusion clinic with leukapheresis capability. Typical patient scenario: older male with mCRPC receiving a three-dose individualized immunotherapy series following confirmation of castration resistance and adequate performance status.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    36415Collection of venous blood by venipuncturePre-procedure labs and serologic testing prior to leukapheresis
    36511Therapeutic apheresis; peripheral blood stem cell harvest for transplantation or collection for cellular therapy, with cell processingRepresents leukapheresis/collection procedure used to obtain autologous cells for sipuleucel-t manufacture (note: institutional billing practices vary)
    96401Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplasticNot directly used for sipuleucel-t infusion; included when concurrent supportive oncology injections are administered
    99024Postoperative follow-up visit, related to routine postoperative careRarely used; may apply for related post-procedural visits depending on payer rules
    96365Intravenous infusion, hydration; initial, up to 1 hourUsed for reporting administration time for IV infusions when payers require an infusion CPT alongside the HCPCS biologic code

    Note: Billing for Q2043 is per infusion; clinical workflow commonly includes 36415 for blood draws and 36511 for the leukapheresis collection procedure. Institutional and payer billing rules determine whether additional CPT infusion administration codes are billed alongside the HCPCS code.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    82Modifier 82 is appended to a surgical CPT code to indicate that an attending physician acted as an assistant because a qualified resident surgeon was unavailable. In teaching hospitals it documents…- When to use: Append modifier 82 in teaching-hospital settings to indicate a physician served as an assistant surgeon because a qualified resident surgeon was unavailable (includes situations where…
    77Modifier 77 indicates that a previously performed procedure or service was legitimately repeated by a different physician or other qualified health care professional. The AMA’s CPT definition…- Use modifier 77 when a basic procedure or service already performed is repeated by a different physician or other qualified health care professional (for example, a second provider independently…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RH0000X
    363L00000X
    246QH0000X
    156FX1201X
    323P00000X
    163WN0800X
    207RA0002X
    177F00000X

    Related ICD-10-CM Codes

    29 rows

    ICD-10-CM CodeDescription
    C61Malignant neoplasm of prostate
    C79.51Secondary malignant neoplasm of bone
    C79.52Secondary malignant neoplasm of bone marrow
    D49.2Neoplasm of unspecified behavior of bone, soft tissue, and skin
    D57.1Sickle-cell disease without crisis
    D61.82Myelophthisis
    E83.52Hypercalcemia
    E87.1Hypo-osmolality and hyponatremia
    F45.41Pain disorder exclusively related to psychological factors
    G89.3Neoplasm related pain (acute) (chronic)

    Showing 1–10 of 29

    Related Payer Policy Updates

    Specialty: Infectious Disease1 / 3

    10 rows

    PolicyPayerEffective Date
    Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    HIV/AIDS Pharmacologic Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    Long-Acting Injectable Antiretroviral Agents for HIVColorado Rocky Mountain Health Plans2026-10-01
    B-Hemolytic Streptococcus TestingOscar Health2026-10-01
    Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance AssaysOscar Health2026-10-01
    Hepatitis Testing (A, B, C, D) Coverage CriteriaOscar Health2026-10-01
    Lyme Disease Testing Coverage CriteriaOscar Health2026-10-01
    Pathogen Panel TestingOscar Health2026-10-01
    Diagnostic Testing of Common Sexually Transmitted InfectionsOscar Health2026-10-01
    Testing for Diagnosis of Active or Latent TuberculosisOscar Health2026-10-01

    Related Codes

    HCPCS-LEVEL-II-Q4139-INJECTABLE-AMNIOMATRIX-BIODMATRIX-1-CC

    HCPCS Q4139: Amniomatrix or Biodmatrix, Injectable, 1 cc

    HCPCS-LEVEL-II-Q4256-AREA-BASED-PROCEDURAL-ADD-ON-PER-SQ-CM

    HCPCS Q4256: MLG-complete Skin Graft Material, Per Sq Cm

    HCPCS-LEVEL-II-Q5132-ADALIMUMAB-AFZB-ABRILADA-10MG-INJECTION

    HCPCS Level II Q5132: Injection, adalimumab-afzb (Abrilada), 10 mg

    HCPCS-Q0035-CARDIOKYMOGRAPHY-CARDIAC-MOTION-RECORDING

    HCPCS Level II Q0035: Cardiokymography

    HCPCS-Q0081-INFUSION-THERAPY-NON-CHEMOTHERAPEUTIC-PER-VISIT

    HCPCS Level II Q0081: Infusion Therapy, Non‑Chemotherapeutic, Per Visit

    HCPCS-Q0083-CHEMOTHERAPY-NON-INFUSION-ADMINISTRATION

    HCPCS Q0083: Chemotherapy Administration, Non-Infusion Methods

    HCPCS-Q0084-CHEMOTHERAPY-INFUSION-ADMINISTRATION-PER-VISIT

    HCPCS Q0084: Chemotherapy Infusion Administration, Per Visit

    HCPCS-Q0085-CHEMOTHERAPY-INFUSION-PLUS-OTHER-TECHNIQUES-PER-VISIT

    HCPCS Q0085: Chemotherapy Infusion Plus Other Technique(s), Per Visit

    HCPCS-Q0091-PAP-SMEAR-SPECIMEN-COLLECTION-TRANSPORT

    HCPCS Q0091: Screening Papanicolaou Smear Collection and Transport

    HCPCS-Q0092-PORTABLE-XRAY-EQUIPMENT-SETUP

    HCPCS Q0092: Set-up Portable X-ray Equipment

    Showing 1–10 of 629

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.